Primary cell lines and 3D model systems can provide in vitro assays of high physiological relevance, but the availability of cells and/or suitable assay technologies limit their application to large scale screening. The use of differentiated stem cells provides a disease- and tissue type-relevant alternative, particularly for investigating disease indications where there is a clear genetic causal link.
View this webinar to learn how human embryonic stem cells were used to develop and validate a 384-well format assay and subsequently conduct a high-throughput screen to identify compounds that modulate mutant protein levels in a neurodegenerative disease, demonstrating how stem cells balance biological relevance and throughput.
- David Cronk, CBiol, MRSB, Director, High-Throughput Screening Services, Charles River
- Bethany Nancolas, PhD, Senior Scientist, Biology, Charles River
- A Novel Human Embryonic Stem Cell-Derived Cell Model for Use in High Content Functional Assays of Neurodegenerative Disorders
- A Comparison of Compounds with Claimed Anti-Fibrotic Activity in Novel Human Fibroblast and Epithelial Transition Assays Using IPF-Derived Patient Material
- SPR Screening: Drug Discovery Applications and Data Processing